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OBJECTIVE—Cardiac ﬁbrosis is an important component of
diabetic cardiomyopathy. Peroxisome proliferator–activated re-
ceptor  (PPAR) ligands repress proinﬂammatory gene expres-
sion, including that of osteopontin, a known contributor to the
development of myocardial ﬁbrosis. We thus investigated the
hypothesis that PPAR ligands could attenuate cardiac ﬁbrosis.
RESEARCH DESIGN AND METHODS—Wild-type cardiomy-
ocyte- and macrophage-speciﬁc PPAR
/ mice were infused
with angiotensin II (AngII) to promote cardiac ﬁbrosis and
treated with the PPAR ligand pioglitazone to determine the
roles of cardiomyocyte and macrophage PPAR in cardiac
ﬁbrosis.
RESULTS—Cardiomyocyte-speciﬁc PPAR
/ mice (cPPAR
/)
developed spontaneous cardiac hypertrophy with increased ven-
tricular osteopontin expression and macrophage content, which
were exacerbated by AngII infusion. Pioglitazone attenuated
AngII-induced ﬁbrosis, macrophage accumulation, and osteopon-
tin expression in both wild-type and cPPAR
/ mice but
induced hypertrophy in a PPAR-dependent manner. We pursued
two mechanisms to explain the antiﬁbrotic cardiomyocyte-
PPAR–independent effects of pioglitazone: increased adiponec-
tin expression and attenuation of proinﬂammatory macrophage
activity. Adenovirus-expressed adiponectin had no effect on
cardiac ﬁbrosis and the PPAR ligand pioglitazone did not
attenuate AngII-induced cardiac ﬁbrosis, osteopontin expression,
or macrophage accumulation in monocyte-speciﬁc PPAR
/
mice.
CONCLUSIONS—We arrived at the following conclusions: 1)
both cardiomyocyte-speciﬁc PPAR deﬁciency and activation
promote cardiac hypertrophy, 2) both cardiomyocyte and mono-
cyte PPAR regulate cardiac macrophage inﬁltration, 3) inﬂam-
mation is a key mediator of AngII-induced cardiac ﬁbrosis, 4)
macrophage PPAR activation prevents myocardial macrophage
accumulation, and 5) PPAR ligands attenuate AngII-induced
cardiac ﬁbrosis by inhibiting myocardial macrophage inﬁltration.
These observations have important implications for potential
interventions to prevent cardiac ﬁbrosis. Diabetes 57:2470–
2479, 2008
P
rogressive cardiac ﬁbrosis found in diabetic car-
diomyopathy and postmyocardial infarction re-
modeling and during pressure overload can
result in diastolic dysfunction leading to reduced
myocardial contractility and, ultimately, heart failure (1–
4). Both angiotensin II (AngII) and aldosterone promote
cardiac hypertrophy, inﬂammation, and ﬁbrosis, whereas
their antagonism improves cardiac function and decreases
mortality in heart failure (5–9). However, little is known
about the cellular mechanism of these effects, and the
prevalence of and mortality from heart failure continues to
increase and is particularly common in subjects with
diabetes (10). We have shown that osteopontin (OPN), a
secreted inﬂammatory glycophosphoprotein, plays a piv-
otal role in cardiac ﬁbrosis (11) and is often increased in
the tissues of diabetic mouse models (11–13). Ventricular
OPN expression is increased during heart failure, parallel-
ing the increase in atrial natriuretic peptide (ANP) expres-
sion, and AngII prominently upregulates OPN in cardiac
cells (12,13). Moreover, OPN knockout (KO) mice develop
less cardiac ﬁbrosis than control mice (11) and are par-
tially protected against streptozotocin-induced diabetic
cardiomyopathy (14).
Peroxisome proliferator–activated receptors (PPARs)
are ligand-activated transcription factors that control ex-
pression of key genes that modulate pathways involved in
fat, lipid, and glucose metabolism; inﬂammation; cell cy-
cle; and immune responses (15). Synthetic PPAR ligands
are insulin sensitizers and have profound anti-inﬂamma-
tory effects, one of which is to decrease OPN expression in
vascular and renal cells (16). Therefore, we hypothesized
that PPAR agonists can attenuate myocardial ﬁbrosis by
reducing OPN expression in cardiomyocytes and/or mac-
rophages, thereby decreasing cardiac inﬂammatory re-
sponses that can result in ﬁbrosis. To test this hypothesis,
we analyzed the effect of a PPAR agonist on cardiac
hypertrophy and ﬁbrosis in an AngII-stimulated model
using both cardiomyocyte- and macrophage-speciﬁc
PPAR KO mice and their wild-type (WT) littermate
controls.
RESEARCH DESIGN AND METHODS
Generation of PPAR-deﬁcient mice. Cardiomyocyte-speciﬁc PPAR KO
(cPPAR
/) mice were bred by mating homozygous PPAR
ﬂox/ﬂox DBA/2J
mice (gift from Dr. F. Gonzalez) (17) with C3H transgenic mice expressing Cre
recombinase under the control of the myosin light chain-2v (MLC2v-Cre)
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2470 DIABETES, VOL. 57, SEPTEMBER 2008promoter (18). The F1 generation was backcrossed with homozygous
PPAR
ﬂox/ﬂox DBA mice to ﬁx the PPAR
ﬂox/ﬂox genotype, and successive
generations were mated with their littermates. Macrophage-speciﬁc PPAR
KO (mPPAR
/) mice (kindly provided by Dr. P. Tontonoz, University of
California Los Angeles) were generated by crossing C57Bl/6 transgenic mice
expressing Cre recombinase under the control of the lysozyme promoter
(LysM-Cre) into homozygous PPAR
ﬂox/ﬂox C57Bl/6 mice (19,20). Mouse
genotypes were determined by PCR (see the online appendix, available at
http://dx.doi.org/10.2337/db07-0924).
Animal procedures. Male mice (3 months of age) were fed chow diet (Harlan
8604) or chow diet supplemented with 2 mg pioglitazone/1g diet and, 2 days
after starting diet, were infused with PBS or a pressor dose of AngII/PBS (2.5
g  kg
1  min
1; Calbiochem) for the indicated treatment intervals by
subcutaneous implantation of osmotic minipumps (DURECT) (21–23). Sys-
tolic blood pressure (SBP) was measured weekly with a tail-cuff system (11).
WT and cPPAR
/ mice were assessed by echocardiography before
minipump implantation and after a 6-week AngII infusion, as previously
described (24). Heart rates were determined during echocardiography (under
anesthesia) and during SBP measurements. No differences were detected
between any of the groups. All animal procedures used in this study were
approved by the University of California Los Angeles Animal Research
Committee.
Morphometric analysis, cardiac ﬁbrosis area, and macrophage content.
Coronal heart sections were cut at the ventricle equator and ﬁxed in 10%
paraformaldehyde/PBS, parafﬁn embedded, and stained with Massons’
trichrome to detect collagen expression. Microscope images were displayed
on a high-resolution monitor, digitized by a video frame grabber (PCVISION
Plus; Imaging Technology, St. Laurent, Canada) running on an IBM-compatible
computer, and areas positively staining for collagen were quantiﬁed with a
morphometric analysis program (Image Pro; Media Cybernetics, Silver Spring,
MD). Contiguous high-power ﬁelds comprising an entire left ventricular
section were analyzed for each sample. Cardiac ﬁbrosis area (blue area) was
expressed as a percentage relative to the entire cardiac cross-sectional area.
Cardiomyocyte diameters were determined from 100 random ﬁbers by a single
operator blinded to the study protocol, essentially as previously described
(25).
Adiponectin overexpression. Adenovirus expressing mouse adiponectin
(Ad-APN) was generated from the full-length cDNA (26), subcloned with an
Adenovirus Expression Vector Kit (Takara Biomedical), propagated in
HEK293 cells, and puriﬁed and quantiﬁed with BD Adeno-X Virus Puriﬁcation
and Rapid Titer kits (BD Biosciences). Adenovirus expressing green ﬂuores-
cent protein (Ad-GFP) was similarly constructed as a control. Male WT and
cPPAR
/ mice (3 months of age) were injected via tail vein with 1  10
8
plaque-forming units of virus 5 days before the start of a 6-week AngII infusion
on chow diet. Plasma adiponectin levels were measured by ELISA (K1002–1;
B-Bridge).
Cardiac gene expression. RNA was isolated from ventricular heart sections
with Trizol reagent (Gibco-BRL, Rockville, MD) and subsequently processed
with RNeasy Mini Kits and RNase-Free DNase (QIAGEN) to remove genomic
DNA from the resulting mRNA samples. Cardiac mRNA samples were reverse
transcribed with random hexamers and MultiScribe RT polymerase (Applied
Biosystems). Real-time quantitative RT-PCR was performed using an ABI
PRISM 7700 to measure gene expression (see online appendix for speciﬁc
primer/probe sets). Gene expression values were normalized against glycer-
aldehyde-3-phosphate dehydrogenase.
Adult mouse cardiomyocyte analyses. Adult mouse cardiomyocyte
(AMCM) cultures were prepared according to Alliance for Cellular Signalling
protocols (27). Immunohistochemistry was performed by standard proce-
dures with speciﬁc antibodies for PPAR (SA-206; Biomol) and myosin (MF
20; Developmental Studies Hybridoma Bank). Macrophage migration assays
were performed in 96-well chambers (CytoSelect CBA-105; Cell Biolabs)
according to the manufacturer’s instructions. Brieﬂy, clariﬁed conditioned
media from a 48-h AMCM culture was placed in the lower compartment of the
chamber, and a 100-l aliquot of a murine J774A.1 macrophage suspension
(5  10
5 cells/ml) in myocyte culture medium was added to the upper
compartment. After 4.5 h, migratory cells were detected with CyQuant GR Dye
(Molecular Probes). Western blot analyses of AMCM protein (20 g) were
performed with a mouse-OPN–speciﬁc antibody (MPIIIB; Developmental
Studies Hybridoma Bank). Stimulation experiments were performed with WT
and cPPAR
/ AMCMs, which were serum-deprived for 1 h, and then
stimulated with AngII and aldosterone (1 mol/l each) as indicated.
Statistical analysis. Data are presented as means  SEM. Data presented in
Figs. 2, 4, and 5 were analyzed by one-way ANOVA due to their three-
treatment design, using Tukey-Kramer multiple comparisons tests to deter-
mine treatment differences between individual means. Genotype differences
between matched treatment groups were analyzed using two-tailed Student’s
t tests. In cases of unequal variance or non-normal distribution, nonparametric
Mann-Whitney two-sample tests or Kruskal-Wallis one-way ANOVAs with
Dunn post hoc analyses were performed to determine signiﬁcant differences
between individual means. A P value 0.05 was considered statistically
signiﬁcant for all tests. Data presented in Tables 1 and 2 and Fig. 3 were
analyzed by two-way ANOVAs due to their 2  2 factor design, and Bonferroni
post hoc analyses were used to identify differences between speciﬁc groups.
In cases of unequal variance or non-normal distribution, data were analyzed
using a linear regression approach in which the continuous data variables
were sorted in ascending order and then assigned rank values (k  1 ,2...,
n), with tied values averaged from the start to the end of the run. Ranked
values were transformed into percentiles using the relationship k/(n  1) and
then transformed into quantiles of the standard normal distribution using the
inverse cumulative normal function, resulting in a symmetric standard normal
distribution with mean zero and variance one. Normal scores were regressed
on indicator variables for treatment, genotype, and genotype-treament inter-
action. The genotype-treatment interaction variable was based on the product
of genotype times treatment. For each outcome variable, the Bonferroni
multiple test procedure was performed to provide t tests for all possible
combinations of treatment and genotype. Bonferroni P values 0.05 per
number of tests were considered statistically signiﬁcant for all analyses.
RESULTS
Cardiomyocyte-speciﬁc PPAR KO (cPPAR
/)
mice have cardiac hypertrophy. cPPAR
/ mice were
created by crossing MLC2v Cre mice, which selectively
delete ﬂoxed target genes in ventricular cardiomyocytes
starting at the early stages of cardiac development (28),
into a homozygous PPAR
ﬂox/ﬂox mouse background. Con-
sistent with the fact that cardiac tissue contains several
cell types in addition to including cardiomyocytes,
cPPAR
/ mice ventricles expressed only 37% less
PPAR mRNA than those of WT littermates (Fig. 1A).
However, PPAR mRNA was not detectable in AMCMs
isolated from cPPAR
/, and confocal microscopy dem-
onstrated complete ablation of cardiomyocyte PPAR
protein expression (Fig. 1B). These data suggest that there
is substantial PPAR expression by other myocardial cell
types. Cardiac PPAR and PPAR	 mRNA expression were
not different in cPPAR
/ and WT mice (data not shown),
suggesting that there were no substantial changes in
cardiac PPAR and PPAR	 mRNA expression to compen-
sate for the loss of cardiomyocyte PPAR expression.
cPPAR
/ mice demonstrated normal reproduction
and life expectancy with no spontaneous pathological
phenotype, despite mild cardiac hypertrophy associated
with increased ventricular atrial natriuretic peptide (ANP)
expression (Table 1). Conversely, the PPAR ligand pio-
glitazone increased ventricular heart–to–body weight ra-
tios and ventricular ANP expression in WT, but not in
cPPAR
/, mice (Table 1). Thus, both cardiomyocyte
PPAR deﬁciency and activation resulted in cardiac hy-
pertrophy. Cardiomyocyte PPAR deﬁciency was also asso-
ciated with differences in cardiomyocyte diameter and
ventricular brain natriuretic peptide (BNP) expression,
while pioglitazone treatment altered cardiomyocyte diam-
eter and ventricular BNP mRNA expression and produced
genotype-speciﬁc effects on heart–to–body weight ratios
and ventricular ANP mRNA expression (Table 1, two-way
ANOVA).
Neither cardiac ﬁbrosis nor transforming growth factor
(TGF)-
1 or ﬁbronectin gene expression, assayed as sur-
rogate markers of cardiac ﬁbrosis, was signiﬁcantly differ-
ent in cPPAR
/ versus WT mice (Fig. 2A–D). However,
cPPAR
/ mice demonstrated a 2.9-fold increase in car-
diac expression of OPN, a proinﬂammatory monocyte
chemoattractant, and a 1.4-fold increase in cardiac expres-
sion of CD68, a marker of macrophage accumulation (Fig.
2E and F), suggesting that cPPAR
/ mice may have
E. CAGLAYAN AND ASSOCIATES
DIABETES, VOL. 57, SEPTEMBER 2008 2471signiﬁcantly increased basal myocardial inﬂammation,
which could promote enhanced myocardial injury during
exposure to cardiac stress.
AngII augments cPPAR
/ versus WT mice cardiac
hypertrophy and ﬁbrosis. To evaluate the role of cP-
PAR in cardiac stress responses, mice were infused with
AngII for 6 weeks at a dose known to cause hypertension,
cardiac hypertrophy, and ﬁbrosis without signiﬁcant
changes in plasma glucose or lipid levels (11,29). AngII
infusion increased ventricular heart–to–body weight ratio
and cardiomyocyte diameter in both genotypes, although
cPPAR
/ mice demonstrated signiﬁcantly greater in-
creases than their WT littermates, despite similar SBP
increases in both groups (Table 1). Ventricular ANP and
BNP mRNA expression was also signiﬁcantly increased by
AngII in both genotypes but did not signiﬁcantly differ
between genotypes (Table 1). Cardiac ﬁbrosis and myo-
cardial expression of TGF-
1 and ﬁbronectin, two ﬁbrosis-
related genes, also signiﬁcantly increased with AngII
infusion in both genotypes. However, whereas AngII in-
duced nearly twofold more cardiac ﬁbrosis in cPPAR
/
than in WT mice (Fig. 2A and B), myocardial TGF-
1 and
ﬁbronectin mRNA expression were similarly induced in
both genotypes (Fig. 2C and D), suggesting that increased
TGF-
1 and ﬁbronectin expression was not responsible
for the increased cardiac ﬁbrosis found in AngII-infused
cPPAR
/ mice. AngII also increased myocardial OPN
and CD68 expression in both genotypes but more so in
cPPAR
/mice, which had increased basal expression of
these genes (PBS infusion, Fig. 2E and F). However, no
changes in heart structure or function were detected by
echocardiography in either genotype after AngII adminis-
tration (data not shown).
Pioglitazone attenuates AngII-induced cardiac ﬁbro-
sis. To determine the ability of cPPAR activation to
attenuate AngII-induced cardiac hypertrophy and ﬁbrosis,
mice were AngII-infused with or without simultaneous
treatment with the PPAR ligand pioglitazone. Cardiomy-
ocyte PPAR deﬁciency was associated with increases in
heart–to–body weight ratios and cardiomyocyte diameters
in AngII-infused mice. Pioglitazone treatment increased
heart–to–body weight ratios and cardiac BNP mRNA
expression in AngII-infused mice but did not alter SBP,
cardiomyocyte diameters, or ventricular ANP mRNA ex-
pression (Table 1, two-way ANOVA). No genotype-speciﬁc
effects of pioglitazone were detected in AngII-infused
mice. Pioglitazone treatment also similarly attenuated
AngII-induced cardiac ﬁbrosis (Fig. 2A and B) and myo-
cardial expression of ﬁbrosis-related (Fig. 2C and D) and
proinﬂammatory (Fig. 2E and F) genes in both cPPAR
/
mice and their WT littermate controls, suggesting that
these antiﬁbrotic and anti-inﬂammatory effects of pioglita-
zone are cardiomyocyte PPAR–independent.
Adiponectin does not attenuate AngII-accelerated
cardiac ﬁbrosis. We hypothesized that the antiﬁbrotic
effect of pioglitazone on AngII-induced cardiac ﬁbrosis
could be mediated through increases in plasma adiponec-
tin because adiponectin overexpression has been reported
to attenuate cardiac hypertrophy in mice (30) and because
pioglitazone treatment increased plasma adiponectin
threefold in AngII-infused cPPAR
/ and WT mice (AngII
10.2  2.6 g/ml vs. AngIIPio 33.9  17.0 g/ml; P 
0.0003). Mice were thus injected with Ad-APN or Ad-GFP
5 days before the start of a 6-week AngII infusion. Ad-APN
markedly increased plasma adiponectin levels, reaching a
peak of 50 times baseline (10-fold pioglitazone induction)
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by study end. Ad-APN attenuated AngII-induced heart–to–
body weight ratio increases in WT mice (5.85  0.18
Ad-GFP vs. 5.21  0.15 Ad-APN; P  0.05) but not in
cPPAR
/ mice (6.48  0.35 Ad-GFP vs. 6.35  0.18
Ad-APN; P  0.79). However, Ad-APN did not attenuate
AngII-induced cardiac ﬁbrosis (Fig. 3A and B) or reduce
myocardial OPN (Fig. 3C) or CD68 (Fig. 3D) mRNA
expression in cPPAR
/ or WT mice. Thus, the increased
systemic adiponectin levels after pioglitazone treatment
were not responsible for attenuation of AngII-induced
cardiac ﬁbrosis and OPN and CD68 expression previously
observed in cPPAR
/ mice with pioglitazone treatment.
PPAR
/ cardiomyocytes support increased macro-
phage chemotaxis. Because cPPAR
/ mice demon-
strated signiﬁcantly more myocardial expression of OPN
and CD68 than WT mice (Fig. 2E and F) and because
macrophages have been implicated in cardiac ﬁbrosis (31),
we hypothesized that cPPAR
/ OPN expression could
promote monocyte accumulation within the myocardium
that could in turn promote cardiac injury in response to
proinﬂammatory stimuli. We found that AMCMs isolated
from cPPAR
/ mice expressed signiﬁcantly more OPN
protein than WT AMCMs (Fig. 4A). AMCM cultures were
stimulated with AngII and aldosterone to simulate the
cardiomyocyte environment during in vivo AngII infusion
because AngII markedly induces adrenal aldosterone se-
cretion. Both cPPAR
/ and WT AMCMs demonstrated
increased OPN mRNA expression when cultured with
AngII and aldosterone, but the addition of pioglitazone
prevented OPN induction only in WT AMCMs (Fig. 4B).
Moreover, cPPAR
/ AMCMs expressed over ﬁvefold
more OPN than WT AMCMs under all culture conditions,
and conditioned media from cPPAR
/ AMCMs stimu-
lated with AngII and aldosterone induced 1.5-fold greater
macrophage migration than WT AMCM supernatant (Fig.
4C). These in vitro data support in vivo observations that
increased OPN expression in cPPAR
/ cardiomyocytes
contributes to increased cardiac macrophage accumulation.
Attenuation of ﬁbrosis by pioglitazone requires mac-
rophage PPAR. Because AngII markedly enhanced car-
diomyocyte OPN expression, cardiomyocyte-mediated
macrophage chemotaxis (Fig. 4B and C), and in vivo
macrophage recruitment (32), we hypothesized that pio-
glitazone could attenuate ﬁbrosis via anti-inﬂammatory
actions on macrophages. Macrophage-speciﬁc PPAR KO
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FIG. 1. PPAR expression in cardiac ventricles and AMCMs. A: Real-time quantitative RT-PCR of ventricular tissue of 4-month-old male WT and
cPPAR
/ mice and pooled AMCMs from male WT (black bars) and cPPAR
/ (gray bars) hearts (n  3/genotype; P < 0.05 by Student’s t test).
Values are normalized to the WT group. B: Immunohistochemistry of AMCMs of male WT and cPPAR
/ (KO) mice. Cardiomyocytes shown are
representative of at least three independent experiments. (Please see http://dx.doi.org/10.2337/db07-0924 for a high-quality digital representa-
tion of this ﬁgure.)
TABLE 2
Cardiac hypertrophy in mPPAR mice
Treatment
SBP (mmHg)* Heart–to–body wt ratio(mg/g) Cardiomyocyte diameter (m)
WT KO WT KO
Two-way
ANOVA WT KO
Two-way
ANOVA
PBSchow diet 103  2 (15) 108  3 (19) 3.9  0.1 (9) 4.1  0.1 (9) 13.4  0.2 (9) 13.7  0.2 (9)
AngIIchow diet 137  7 (7) 148  4 (12) 5.6  0.1 (9) 5.4  0.1 (12) 14.4  0.1 (9) 14.4  0.2 (12)
AngIIPio 141  8 (8) 142  3 (9) 5.9  0.2 (11) 5.9  0.3 (9) Drug† 14.6  0.1 (11) 14.8  0.2 (9) Drug†
Data are means  SD (n). PBS- and AngII-infused groups were analyzed separately because comparision between AngII- and PBS-infused
groups revealed signiﬁcant increases in all phenotypes upon AngII infusion (P  0.05; one-way ANOVA). Differences in PBSchow
diet–treated mice were analyzed with Student’s t test. AngII-infused groups were analyzed with two-way ANOVAs to identify statistically
signiﬁcant differences (P  0.05) in factor level means due to genotype (gene), treatment (drug), or the interaction between genotype and
treatment (interaction), and Bonferroni post-test analyses were used to identify signiﬁcant differences (P  0.05) in parameter means due
to genotype or treatment effects between speciﬁc groups. SBP and heart–to–body weight data from AngII-infused mice were transformed
prior to analysis to account for differences in normality or SDs within these groups (see research design and methods). Both heart–to–body
weight ratio and cardiomyocyte diameter values demonstrated signiﬁcant differences due to treatment by two-way ANOVA, but no signiﬁcant
differences were detected between group means in the post hoc analyses. *SBP data were analyzed by both one- and two-way ANOVA. No
signiﬁcant differences were detected by either method. †Two-way ANOVA comparing AngIIchow diet and AngIIPio data.
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/) mice, previously described by Babaev et al.
(33), were thus analyzed using the same treatment proto-
col to address the role of macrophage PPAR in cardiac
ﬁbrosis. After 6 weeks, PBS-infused mPPAR
/ and WT
mice demonstrated similar cardiac ﬁbrosis, and AngII-
infused mPPAR
/ and WT mice demonstrated similar
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2474 DIABETES, VOL. 57, SEPTEMBER 2008cardiac ﬁbrosis increases, which were substantially
greater than in cPPAR
/ and cPPAR
/ mice (data not
shown), likely due to the different genetic backgrounds of
these mice. To study the effect of pioglitazone on similar
levels of cardiac ﬁbrosis in these two mouse models,
mPPAR mice were studied after 2 weeks of AngII infu-
sion (Table 2 and Fig. 5A), at which time they developed
cardiac hypertrophy and ﬁbrosis levels comparable with
those of cPPAR mice that received 6 weeks of AngII
infusion (Table 1 and Fig. 3A). After 2 weeks, PBS-infused
mPPAR
/ and mPPAR
/ mice had similar heart–to–
body weight ratios and cardiomyocyte diameters (Table
2), cardiac ﬁbrosis and myocardial OPN and CD68 mRNA
expression (Fig. 5A–D), and circulating monocyte levels
(data not shown). Pioglitazone increased AngII-mediated
cardiac hypertrophy independent of genotype in mPPAR
mice (Table 2, two-way ANOVA), but reduced AngII-
mediated cardiac ﬁbrosis and OPN and CD68 gene expres-
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FIG. 3. Adiponectin does not mediate the antiﬁbrotic effect of pioglitazone in the heart. Male cPPAR mice were infected with adenovirus
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cPPAR
/ or WT mice injected with Ad-GFP vs. Ad-APN, and adenovirus effects did not differ according to genotype (P > 0.05 by two-way
ANOVA). Values for WT mice are depicted by black bars and cPPAR
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a high-quality digital representation of this ﬁgure.)
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/ but not in mPPAR
/ mice (Fig.
5A–D). This data suggests that macrophage mPPAR was
required for the antiﬁbrotic actions of pioglitazone ob-
served in AngII-infused mPPAR
/ (Fig. 5A) as well as
cPPAR
/ and cPPAR
/ mice (Fig. 3A). Thus, the
macrophage appears to be a key mediator of ﬁbrosis in the
heart.
DISCUSSION
Although PPAR ligands can promote edema by increasing
renal sodium reabsorption to exacerbate heart failure (34),
the metabolic and anti-inﬂammatory effects of these
agents are implicated in cardiovascular protection (35).
Indeed, a recent analysis of patients developing congestive
heart failure with thiazolidinediones suggests that correc-
tion of heart failure is not associated with worsening of
ejection fraction, which usually occurs with repeated
bouts of congestive heart failure (36). We used an AngII-
dependent cardiac ﬁbrosis model in this study 1) because
AngII is a potent proﬁbrotic factor (37) and patients with
type 2 diabetes may have increased renin-angiotensin-
aldosterone system (RAAS) activity due to increases in
adipose-derived angiotensinogen (38) and 2) because,
importantly, PPAR ligand effects on ﬁbrosis could be
studied in the absence of plasma glucose and lipid changes
(11,29). We report herein that PPAR ligands attenuate
cardiac ﬁbrosis via a mechanism that requires monocyte,
but not cardiomyocyte, PPAR. cPPAR
/ mice had no
apparent pathology, except for a mild cardiac hypertro-
phy, in the absence of an external stress. However, AngII
infusion nearly doubled cardiac ﬁbrosis and OPN expres-
sion in cPPAR
/ mice relative to WT littermates. Iso-
lated cPPAR
/ AMCMs had more than a ﬁvefold
increase in OPN mRNA expression versus cPPAR
/
AMCMs, and conditioned media of cPPAR
/ AMCMs
demonstrated 1.5-fold more monocyte chemoattractant
activity than cPPAR
/ AMCMs. Increased cPPAR
/
cardiomyocyte OPN expression may contribute to in-
creased monocyte accumulation both in the basal state
and following AngII infusion, when inﬂammation plays a
prominent role in cardiac ﬁbrosis. However, noncardiom-
yocyte-driven inﬂammation appears critical to the cardiac
ﬁbrosis process in this model because pioglitazone atten-
uated cardiac ﬁbrosis and ventricular OPN, TGF-
1,ﬁ -
bronectin, and CD68 mRNA expression in cPPAR
/ and
cPPAR
/ mice, but not in mPPAR
/ and mPPAR
/
mice. Taken together, our data suggest that 1) mecha-
nisms contributing to initiation of cardiac hypertrophy are
different from those contributing to initiation of cardiac
ﬁbrosis, 2) cardiomyocyte PPAR activation or deﬁciency
contributes to cardiac hypertrophy, 3) inﬂammation is a
signiﬁcant driver of AngII-induced cardiac ﬁbrosis, 4) both
cardiomyocyte and macrophage PPAR regulate cardiac
macrophage inﬁltration, and 5) PPAR ligands attenuate
AngII-induced cardiac ﬁbrosis by inhibiting macrophage
inﬁltration into the myocardium.
Since pioglitazone treatment prominently increased
plasma adiponectin, we also examined whether increased
plasma adiponectin might explain the antiﬁbrotic effect of
pioglitazone, independent of cardiomyocyte PPAR activ-
ity. Cardiac hypertrophy and mortality, induced by aortic
constriction or AngII infusion, is rescued by adenoviral
adiponectin in adiponectin-deﬁcient mice (30). However,
whereas pioglitazone improved AngII-induced cardiac ﬁ-
brosis and increased plasma adiponectin in both WT and
cPPAR
/ mice, adiponectin overexpression had no
effect on cardiac ﬁbrosis in either genotype and attenu-
ated cardiac hypertrophy only in WT mice. Thus, adi-
ponectin does not appear to impact ﬁbrosis. The
question of why cardiomyocyte PPAR was required for
attenuation of cardiac hypertrophy by adiponectin re-
quires further investigation.
Cardiac PPAR deﬁciency, in this study and previous
reports, is associated with cardiac hypertrophy and
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FIG. 4. PPAR
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each) with or without 1 mol/l pioglitazone. WT values are depicted by black bars and cPPAR
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vs. WT by one-way ANOVA). Pio, pioglitazone.
CARDIOMYOCYTE AND MACROPHAGE PPAR IN CARDIAC FIBROSIS
2476 DIABETES, VOL. 57, SEPTEMBER 2008greater hypertrophic responses to stress (39,40). Similar to
Duan et al. (40), we found that PPAR activation induced
cardiac hypertrophy, which was not detectable by echo-
cardiography and which occurred without spontaneous
systolic or diastolic dysfunction. Cardiac hypertrophy in
their model was associated with activation of the nuclear
factor B pathway (40). In their study, however, the
PPAR ligand rosiglitazone induced cardiac hypertrophy
in both the WT and KO animals, leading the authors to
conclude that cardiomyocyte PPAR only partially medi-
ated the effect. They proposed that rosiglitazone stimu-
lated the p38 mitogen-activated protein kinase pathway to
activate cardiac hypertrophy through a mechanism dis-
tinct from that mediated by cardiomyocyte PPAR (40).
Cardiac phenotype differences between the present study
and that of Duan et al. may result from genetic differences
in the two models (MLC2v Cre vs. MHC Cre) or differ-
ences in pioglitazone versus rosiglitazone effects. Neither
thiazolidinedione has been shown to cause cardiac hyper-
trophy in humans (41,42).
RAAS-induced inﬂammation contributes to the patho-
genesis of cardiac ﬁbrosis. Cardiac OPN expression is
increased by activation of both cardiac AngII type 1
receptors and mineralocorticoid receptors (37). We previ-
ously reported that cardiac OPN expression is elevated in
rodent models of cardiac hypertrophy and in ventricles of
explanted hearts from humans receiving cardiac trans-
plants (13). OPN promotes cardiac ﬁbroblast attachment
to the extracellular matrix (ECM), and cardiac ﬁbroblast
growth and ECM production (12,43), whereas OPN-
deﬁcient mice have attenuated cardiac ﬁbrosis, suggesting
that OPN is a key proﬁbrotic factor in the heart (11,44,45).
None of these studies differentiated between the contri-
butions of cardiomyocyte versus macrophage OPN de-
ﬁciency in attenuating cardiac ﬁbrosis, although we
reported that macrophage OPN deﬁciency attenuated
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phage attachment and chemotaxis and by promoting
macrophage apoptosis (46).
In this study, we found that cardiac OPN expression and
macrophage accumulation were markedly increased in
nonstressed cPPAR
/ mice. Although increased cardiac
OPN expression could result from increased macrophage
accumulation, isolated cPPAR
/ AMCMs also expressed
more OPN than WT AMCMs, suggesting that both macro-
phages and cardiomyocytes contribute to elevated cardiac
OPN expression in cPPAR
/ mice. We did not, how-
ever, observe increased cardiac ﬁbrosis in nonstressed
cPPAR
/ mice, even in 1-year-old mice, indicating that
the increased cardiac OPN expression was not associated
with spontaneous cardiac pathology during this time
frame. Because OPN is a macrophage chemoattractant,
increased cardiac OPN secretion could lead to cardiac
macrophage accumulation, as observed in AngII-infused
mice, further increasing myocardial OPN expression and
creating a vicious cycle that could escalate the cardiac
ﬁbrotic process.
This study underscores a role for macrophages in car-
diac ﬁbrosis and a possible role for PPAR ligands in the
inhibition of cardiac ﬁbrosis. Pioglitazone decreased car-
diac ﬁbrosis, macrophage accumulation, and OPN expres-
sion in cPPAR
/, cPPAR
/, and mPPAR
/ mice,
suggesting that macrophage accumulation and OPN ex-
pression is a major mechanism of cardiac ﬁbrosis induced
by RAAS activation. PPAR ligands suppress macrophage
OPN expression (47), attenuate macrophage expression of
several pro-inﬂammatory genes, and inhibit monocyte
chemotaxis (48). Pioglitazone did not, however, attenuate
cardiac ﬁbrosis in mice with a monocyte-speciﬁc PPAR
deﬁciency, suggesting that PPAR is required for the
attenuation of monocyte inﬂammatory behavior that leads
to cardiac ﬁbrosis. Thus, the anti-inﬂammatory actions of
PPAR ligands may be useful for attenuating cardiac
ﬁbrosis and may be an adjunct therapy to RAAS inhibition.
However, these putative anti-inﬂammatory cardiac actions
of PPAR need to be conﬁrmed in humans. Further studies
are also necessary to determine whether the metabolic
and insulin-sensitizing effects of PPAR ligands are also
cardiomyocyte protective in diabetes and obesity and
whether weaker insulin-sensitizing PPAR ligands that
cause less edema, which are currently under development,
also attenuate cardiac ﬁbrosis.
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